Shanghai Rightongene Biotechnology Co Ltd
SSE:688217
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Rightongene Biotechnology Co Ltd
SSE:688217
|
CN |
|
Nyxoah SA
XBRU:NYXH
|
BE |
|
Lar Espana Real Estate SOCIMI SA
MAD:LRE
|
ES |
|
Hakuyosha Co Ltd
TSE:9731
|
JP |
|
Lu Thai Textile Co Ltd
SZSE:000726
|
CN |
|
G
|
G3 Exploration Ltd
LSE:G3E
|
CN |
|
K
|
Keypath Education International Inc
ASX:KED
|
US |
Shanghai Rightongene Biotechnology Co Ltd
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. The company is headquartered in Shanghai, Shanghai and currently employs 503 full-time employees. The company went IPO on 2021-05-17. The firm's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The firm mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The firm also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The firm mainly conducts its businesses within domestic market.
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. The company is headquartered in Shanghai, Shanghai and currently employs 503 full-time employees. The company went IPO on 2021-05-17. The firm's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The firm mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The firm also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The firm mainly conducts its businesses within domestic market.
